Medications broadly increasing 5‐HT bioavailability are effective for treating human obesity and commonly improve insulin sensitivity and glycaemic control in obese patients with type 2 diabetes by promoting weight loss. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.